- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02323646
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
June 17, 2019 updated by: Repros Therapeutics Inc.
A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
The primary objective of this study is to determine the safety and efficacy of two vaginal doses of Proellex® administered for up to 2 courses of treatment (18 weeks each), each separated by an Off-Drug Interval (ODI), to premenopausal women with symptomatic uterine fibroids.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316
-
-
Georgia
-
Sandy Springs, Georgia, United States, 30328
-
-
Louisiana
-
Metairie, Louisiana, United States, 70001
-
-
Michigan
-
Saginaw, Michigan, United States, 48604
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
-
-
Texas
-
Houston, Texas, United States, 77030
-
Houston, Texas, United States, 77054
-
-
Virginia
-
Richmond, Virginia, United States, 23235-4759
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 47 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Adult females between 18 and 47 years.
- Have a history of at least 3 regular menstrual cycles in which menorrhagia is due to uterine fibroids.
- Must have uterine fibroids.
- Agreement not to attempt to become pregnant during the trial.
- Agreement to use only sanitary pads provided throughout the course of the study, tampon use is prohibited .
- Ability to complete a daily Participant diary and study procedures in compliance with the protocol.
- Have a negative pregnancy test at the Screening and Baseline visits, and subsequent study visits.
- A Body Mass Index (BMI) between 18 and 45 inclusive.
- Menstrual blood loss > 80 milliliters (mL) by alkaline hematin assay.
Exclusion Criteria:
- Post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy.
- Pregnant or lactating or is attempting or expecting to become pregnant during the entire study period.
- Received an investigational drug in the 30 days prior to the screening for this study.
- History of Polycystic Ovarian Syndrome (PCOS).
- Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, Dihydroepiandrosterone (DHEA) or hormonal products for at least 2 weeks prior to screening and during the study.
- Use of oral contraceptives in the preceding 30 days. Use of Depo-Provera® in the preceding 10 months.
- Use of Gonadotropin Releasing Hormone (GnRHas) (e.g. Lupron Depot) within 3 months of the first dose of study drug (Lupron Depot must have a wash-out period of 3 months).
- Has an Intra Uterine device (IUD) in place.
- Known or suspected carcinoma of the breast or reproductive organs.
- Recent history (within past 6 months) of alcoholism or drug abuse.
- Clinically significant abnormal findings on screening examination and laboratory assessments or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Following the baseline assessment no treatment period, matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
|
Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
|
Experimental: Telapristone Acetate 6 mg
Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
|
Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Other Names:
|
Experimental: Telapristone Acetate 12 mg
Following the baseline assessment no treatment period, telapristone acetate 12mg, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
|
Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants in Amenorrhea at the End of Treatment Course 1
Time Frame: At the end of 18-weeks Treatment Course 1
|
Amenorrhea was defined as any 28-day period during treatment (not including the ODI) without a bleeding intensity score >1.
Participants were provided with a daily diary and Pictorial Blood Loss Assessment Chart (PBAC) to record information about the menstrual blood loss (MBL).
Bleeding intensity was graded on a 5-point scale where: 1=spotting to 5=heavy bleeding.
|
At the end of 18-weeks Treatment Course 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants in Amenorrhea at the End of Treatment Course 2
Time Frame: At the end of 18-weeks Treatment Course 2
|
Amenorrhea was defined as any 28-day period during treatment (not including the ODI) without a bleeding intensity score >1 after 2 courses of treatment.
Participants were provided with a daily diary and (PBAC) to record information about the MBL.
Bleeding intensity was graded on a 5-point scale where: 1=spotting to 5=heavy bleeding.
|
At the end of 18-weeks Treatment Course 2
|
Percentage Change in PBAC Scores From Baseline to the End of Treatment Courses 1 and 2
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1 and the end of 18-weeks Treatment Course 2
|
Uterine bleeding was assessed with the use of the PBAC, a validated self-reporting method to estimate menstrual blood loss.
Participants recorded daily the number of tampons and towels used and the degree to which individual items were soiled with blood (plus small or large clots).
Pictorial scores range from score 1 for slightly stained tampon/towel, 5 for a partially stained tampon/towel, 10 for a completely saturated tampon, 20 for a completely saturated towel, and 5 for each episode of flooding and for each blood clot larger than a quarter in size.
Total score can range from 0 (no bleeding) to >500.
Higher scores indicate more bleeding.
Lower scores indicate less bleeding.
A negative change from Baseline indicates improvement (reduction in bleeding).
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1 and the end of 18-weeks Treatment Course 2
|
Percentage Change in Transformed Total Uterine Fibroid System Quality of Life Survey System Severity (UFS-SSS) Score From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
Each question was answered on a 5-point scale where 1=Not at all to 5=A very great deal.
The sum of the total scores was transformed to a range of 0=no symptoms (best) to 100=most severe symptoms (worst).
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in the Individual UFS-SSS Subscale Score Question 1 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
The participant answered UFS-SSS subscale question 1: During the previous 3 months how distressed were you by "heavy bleeding during your menstrual period"?
using a 5-point scale where 1=Not at all to 5=A very great deal.
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in the Individual UFS-SSS Subscale Score Question 2 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
The participant answered UFS-SSS subscale question 2: During the previous 3 months how distressed were you by "passing blood clots during your menstrual period"?
using a 5-point scale where 1=Not at all to 5=A very great deal.
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in the Individual UFS-SSS Subscale Score Question 3 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
The participant answered UFS-SSS subscale question 3: During the previous 3 months how distressed were you by "fluctuation in the duration of your menstrual period compared to your previous cycle"?
using a 5-point scale where 1=Not at all to 5=A very great deal.
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in the Individual UFS-SSS Subscale Score Question 4 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
The participant answered UFS-SSS subscale question 4: During the previous 3 months how distressed were you by "fluctuation in the length of your monthly cycle compared to your previous cycles"?
using a 5-point scale where 1=Not at all to 5=A very great deal.
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in the Individual UFS-SSS Subscale Score Question 5 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
The participant answered UFS-SSS subscale question 5: During the previous 3 months how distressed were you by "feeling tightness or pressure in your pelvic area"?
using a 5-point scale where 1=Not at all to 5=A very great deal.
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in the Individual UFS-SSS Subscale Score Question 6 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
The participant answered UFS-SSS subscale question 6: During the previous 3 months how distressed were you by "frequent urination during the daytime hours"?
using a 5-point scale where 1=Not at all to 5=A very great deal.
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in the Individual UFS-SSS Subscale Score Question 7 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
The participant answered UFS-SSS subscale question 7: During the previous 3 months how distressed were you by "frequent nighttime urination"? using a 5-point scale where 1=Not at all to 5=A very great deal.
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in the Individual UFS-SSS Subscale Score Question 8 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
UFS-SSS is an 8 question assessment tool used to measure symptom severity and has been validated as a three month look back questionnaire.
The participant answered UFS-SSS subscale question 8: During the previous 3 months how distressed were you by "feeling fatigued"?
using a 5-point scale where 1=Not at all to 5=A very great deal.
A negative percentage change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1, the end of 18-weeks Treatment Course 2 and the Course 2 Week 24 Follow-up Visit
|
Percentage Change in Total Uterine Fibroid Volume From Baseline to the End of Treatment Courses 1 and 2
Time Frame: Baseline (No treatment period) to the end of 18-weeks Treatment Course 1 and the end of 18-weeks Treatment Course 2
|
The total uterine fibroid volume was measured by Magnetic Resonance Imaging (MRI).
A negative change from Baseline indicates improvement.
|
Baseline (No treatment period) to the end of 18-weeks Treatment Course 1 and the end of 18-weeks Treatment Course 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 12, 2015
Primary Completion (Actual)
April 6, 2017
Study Completion (Actual)
April 6, 2017
Study Registration Dates
First Submitted
December 18, 2014
First Submitted That Met QC Criteria
December 22, 2014
First Posted (Estimate)
December 23, 2014
Study Record Updates
Last Update Posted (Actual)
June 25, 2019
Last Update Submitted That Met QC Criteria
June 17, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZPV-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Fibroids
-
IceCure Medical Ltd.Withdrawn
-
The Cleveland ClinicCompletedUterine Fibroids, Menorrhagia, EndometriosisUnited States
-
Trieu, Nguyen Thi, M.D.Completed
-
Elizabeth A. StewartCompletedUterine Fibroids | Myomas | Uterine Leiomyomas | FibroidsUnited States
-
Instituto Valenciano de Infertilidad, IVI VALENCIATerminated
-
Mayo ClinicEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedUterine Fibroids | Myomas | Fibroids | Symptomatic Uterine LeiomyomasUnited States
-
Acessa Health, Inc.Active, not recruiting
-
InSightecTerminatedUterine Fibroids, With Unexplained InfertilityUnited States
-
AbbVieEnrolling by invitation
-
Mirabilis Medica, Inc.CompletedUterine Fibroids (Leiomyomas)Mexico
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy